ERBB2 and breast carcinoma: Ongoing clinical trials (NCT03881605, NCT03617341, NCT04030507) are investigating the potential utility of proactive screening strategies in selected patients at increased risk for brain metastases (BM), such as those with metastatic HER2-positive breast cancer.